Ledger.Open graph →
SEC Form D · filed September 27, 2022

Akari Therapeutics Plc

Offering
$12.8M
Sold
$12.8M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
LONDON, United Kingdom
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (26)

David Byrne · London, United KingdomDirectorDonald Williams · London, United KingdomDirectorMichael Grissinger · London, United KingdomDirectorRay Prudo · London, United KingdomDirectorStuart Ungar · London, United KingdomDirectorJames Hill · London, United KingdomDirectorRachelle Jacques · London, United KingdomExec · DirectorAike Ho · Oakland, CADirectorJeffrey Zhao · West Hollywood, CADirectorSara Y. Huda · Grand Duchy of Luxembourg, LuxembourgDirectorEric Wiesen · Oakland, CADirectorJeffrey O'Donohue · TOLUCA LAKE, CADirectorGerard Cuddy · Irvine, CADirectorTorsten Hombeck · London, United KingdomExecMelissa Bradford-Klug · London, United KingdomExecMiles Nunn · London, United KingdomExecMariel A. Joliet · HOUSTON, TXDirectorGeorge E. Marucci, Jr · HOUSTON, TXDirectorSusan C. Schnabel · HOUSTON, TXDirectorDouglas L. Goodwillie · HOUSTON, TXDirectorMichael J. O'Neil · HOUSTON, TXDirectorJohn B. Riley · HOUSTON, TXDirectorMelissa Bradford-Klug · London, United KingdomExecTorsten Hombeck · London, United KingdomExecRachelle Jacques · London, United KingdomExec · DirectorMiles Nunn · London, United KingdomExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗